Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director or Manager (PDMR), rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It details a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment.
- Transaction Date: July 14, 2016.
- Price: £16.6781 per share.
- Volume: 102.401 shares.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely discloses the acquisition of shares by Mrs. K Thomson, a PCA of Mr. P C Thomson (SVP, Communications & Government Affairs).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is a regulatory disclosure of a specific insider-related transaction.
Investor Verification Checklist
- Verify the identity of the PCA (Mrs. K Thomson) and her relationship to the PDMR (Mr. P C Thomson).
- Confirm the transaction price (£16.6781) aligns with the market price on July 14, 2016.
- Note that this filing does not reflect the company's overall financial performance for the period.